TCA Cellular Therapy

TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatments for serious and life-threatening diseases. The company utilizes single or a combination of autologous (patient’s own) adult stem cells to treat various diseases, related to the cardiovascular, nervous, skeletal and muscular systems. Six FDA-approved clinical trials at Phases I, II and/or II/III are underway to treat Heart Disease, Peripheral Vascular Disease (PVD), Peripheral Arterial Disease (PAD), Limb Ischemia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) and Spinal Cord Injuries. TCA-CT’s adult stem cell research allows us to produce a marketable biological product to regenerate damaged blood vessels and organs. As soon as Phase III studies are completed and approved by the FDA for the United States market, the adult stem cell products developed by TCA-CT will be transplanted into humans as treatments for a variety of diseases.